Literature DB >> 27061226

Histological validation of cardiac magnetic resonance T1 mapping for detecting diffuse myocardial fibrosis in diabetic rabbits.

Mu Zeng1, Nan Zhang1, Yi He1, Zhaoying Wen1, Zhanhong Wang1, Yike Zhao1, Andreas Greiser2, Jing An3, Tianjing Zhang3, Bin Jing4, Xin Zhang5, Zhanming Fan6, Debiao Li7.   

Abstract

PURPOSE: To pathologically verify the correlation between native T1 mapping, postcontrast T1 mapping, and extracellular volume fraction (ECV) and myocardial diffuse fibrosis, as determined by collagen volume fraction (CVF).
MATERIALS AND METHODS: Thirty New Zealand white rabbits were randomly divided into the control group (n = 6), diabetes 3 months group (n = 8), diabetes 6 months group (n = 8), and diabetes 9 months group (n = 8). All the rabbits underwent clinical 3.0T magnetic resonance (MR) examinations with pre- and postcontrast modified Look-Locker inversion recovery T1 mapping. For the histological study, each rabbit was sacrificed after MR scanning, hematoxylin and eosin and Masson staining of the left ventricular myocardium were performed, and CVF was calculated. Pre- and postcontrast T1 values and ECV were compared to CVF using Pearson's correlation coefficients.
RESULTS: Two rabbits died in each diabetes group, thus each group included six rabbits. ECV calculated from pre- and postcontrast T1 values showed a very strong correlation with CVF (r = 0.876, P < 0.001), whereas postcontrast T1 values exhibited a moderate correlation with CVF (r = -0.564, P = 0.004). In contrast, precontrast T1 values showed no correlation with CVF (r = 0.311, P = 0.139).
CONCLUSION: ECV has a very strong correlation with pathological CVF, and can be used to assess the degree of diffuse myocardial fibrosis better than the postcontrast T1 value. Precontrast T1 value has no significant correlation with diffuse myocardial fibrosis. J. Magn. Reson. Imaging 2016;44:1179-1185.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  ECV; T1 mapping; diabetic rabbit; diffuse myocardial fibrosis; native T1 value; postcontrast T1 value

Mesh:

Year:  2016        PMID: 27061226     DOI: 10.1002/jmri.25268

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

Review 1.  Redefining the role of biomarkers in heart failure trials: expert consensus document.

Authors:  Frank Kramer; Hani N Sabbah; James J Januzzi; Faiez Zannad; J Peter van Tintelen; Erik B Schelbert; Raymond J Kim; Hendrik Milting; Richardus Vonk; Brien Neudeck; Richard Clark; Klaus Witte; Wilfried Dinh; Burkert Pieske; Javed Butler; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

2.  Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain.

Authors:  Yukun Cao; Wenjuan Zeng; Yue Cui; Xiangchuang Kong; Miao Wang; Jie Yu; Shan Zhang; Jing Song; Xu Yan; Andreas Greiser; Heshui Shi
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

3.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).

Authors:  Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-09       Impact factor: 5.364

4.  Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.

Authors:  Peter P Swoboda; Adam K McDiarmid; Bara Erhayiem; David P Ripley; Laura E Dobson; Pankaj Garg; Tarique A Musa; Klaus K Witte; Mark T Kearney; Julian H Barth; Ramzi Ajjan; John P Greenwood; Sven Plein
Journal:  J Am Heart Assoc       Date:  2017-07-17       Impact factor: 5.501

5.  CMR-derived ECVs vary with myocardial region and associate with the regional wall thickness.

Authors:  Mao-Yuan Su; Kuei-Yuan Hou; Ming-Hung Liu; Tien-Min Lin; Jyh-Ming Jimmy Juang; Lian-Yu Lin; Cho-Kai Wu; Hsi-Yu Yu; Shun-Chung Yang; Yu-Sen Huang; Emi Niisato; Yeun-Chung Chang
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

6.  Adverse fibrosis remodeling and aortopulmonary collateral flow are associated with poor Fontan outcomes.

Authors:  Andrea Pisesky; Marjolein J E Reichert; Charlotte de Lange; Mike Seed; Shi-Joon Yoo; Christopher Z Lam; Lars Grosse-Wortmann
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-15       Impact factor: 5.364

7.  Multiparametric CMR imaging of myocardial structure and function changes in diabetic mini-pigs with preserved LV function: a preliminary study.

Authors:  Yukun Cao; Heshui Shi; Guozhu Shao; Yue Cui; Xiaoyu Han; Jia Liu; Yumin Li; Na Li
Journal:  BMC Cardiovasc Disord       Date:  2022-04-02       Impact factor: 2.298

8.  T1 values and extracellular volume fraction in asymptomatic subjects: variations in left ventricular segments and correlation with cardiovascular risk factors.

Authors:  Moon Young Kim; Soo Jin Cho; Hae Jin Kim; Sung Mok Kim; Sang-Chol Lee; MunYoung Paek; Yeon Hyeon Choe
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996

9.  MR extracellular volume mapping and non-contrast T1ρ mapping allow early detection of myocardial fibrosis in diabetic monkeys.

Authors:  Yu Zhang; Wen Zeng; Wei Chen; Yushu Chen; Tong Zhu; Jiayu Sun; Zhigang Liang; Wei Cheng; Lei Wang; Bing Wu; Li Gong; Victor A Ferrari; Jie Zheng; Fabao Gao
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

10.  Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes.

Authors:  Annemie Stege Bojer; Martin Heyn Sørensen; Niels Vejlstrup; Jens P Goetze; Peter Gæde; Per Lav Madsen
Journal:  Cardiovasc Diabetol       Date:  2020-10-22       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.